Liraglutide
GLP-1 · s.c. daily · Novo Nordisk / generics
Summary
- Also known as
- Saxenda / generics
- Mechanism
- GLP-1
- Route
- s.c. daily
- Company
- Novo Nordisk / generics
- Highest development stage
- approved
- Status (as of data cut)
- Approved for obesity (2014); generics available verify
- Next milestone
- —
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | FDA and EMA: Saxenda | Saxenda EPAR |
| T2D | 4 approved / in label | FDA and EMA: Victoza | Victoza EPAR |
| CV outcomes | 4 approved / in label | FDA label (Victoza): MACE reduction in T2D with established CVD | LEADER |
| CKD | 1 phase 2 / signal | Kidney outcomes only as a LEADER secondary endpoint; no dedicated phase 3 | LEADER |
| HFpEF | 1 phase 2 / signal | Phase 2 only | |
| MASH | 1 phase 2 / signal | Phase 2 only (LEAN) | |
| Sleep apnoea | 3 positive phase 3 | Positive phase 3 (SCALE Sleep Apnea, results posted); not a labelled indication | SCALE Sleep Apnea |
| Knee OA | -1 negative phase 3/4 | LOSEIT (phase 4): no reduction in knee pain versus placebo after diet-induced weight loss | LOSEIT |
| Alzheimer's | 1 phase 2 / signal | Phase 2b (ELAD) only |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
Liraglutide US label 27.07.2026
1 INDICATIONS AND USAGE Liraglutide Injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use : Liraglutide Injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Limitations of Use : Coadministration with other liraglutide-containing products is not recommended.
Victoza US label 14.10.2025
1 INDICATIONS AND USAGE VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use: VICTOZA contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. (1) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) Limitations of Use : • Coadministration with other liraglutide-containing products is not recommended.
Xultophy 100/3.6 US label 14.10.2025
1 INDICATIONS AND USAGE XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [see Warnings and Precautions ( 5.5 )]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin. XULTOPHY 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : ( 1 ) • Coadministration with any other product containing liraglutide or another GLP-1 receptor agonist is not recommended. • Not recommended for the treatment of diabetic ketoacidosis. • Has not been studied in combination with prandial insulin.
liraglutide US label 18.06.2026
1 INDICATIONS AND USAGE Liraglutide injection is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. The safety and effectiveness of liraglutide injection in pediatric patients with type 2 diabetes have not been established. Liraglutide injection is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and Pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: Coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. ( 1 ) The safety and effectiveness of liraglutide injection in pediatric patients with type 2 diabetes have not been established. ( 1 )
Saxenda US label 25.02.2026
1 INDICATIONS AND USAGE SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. • Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: • Coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. ( 1 ) • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ( 1 )
LIRAGLUTIDE US label 12.03.2026
1 INDICATIONS AND USAGE Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use : Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) Limitations of Use: Coadministration with other liraglutide-containing products is not recommended.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Outcome trials
Cardiovascular and kidney outcome trials
LEADER liraglutide 1.8 mg vs placebo · T2D at high CV risk · n = 9340 · 2016 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death, nonfatal (including silent) MI, or nonfatal stroke | 0.87 | 0.78–0.97 | 608 vs 694 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.78 | 0.66–0.93 | 219 vs 278 | verified |
| All-cause death Death from any cause | 0.85 | 0.74–0.97 | 381 vs 447 | verified |
| Myocardial infarction Myocardial infarction (fatal or nonfatal); not prespecified analysis | 0.86 | 0.73–1.00 | 292 vs 339 | verified |
| Stroke Stroke (fatal or nonfatal); not prespecified analysis | 0.86 | 0.71–1.06 | 173 vs 199 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure | 0.87 | 0.73–1.05 | 218 vs 248 | verified |
| Kidney composite Nephropathy: new-onset persistent macroalbuminuria, doubling of serum creatinine with eGFR <=45, continuous renal-replacement therapy, or death from renal disea | 0.78 | 0.67–0.92 | 268 vs 337 | verified |
| Expanded MACE (MACE + HF hosp. + revasc. + UA) Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure | 0.88 | 0.81–0.96 | 948 vs 1062 | verified |
| Retinopathy complications Retinopathy: need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or onset of diabetes-related blindness | 1.15 | 0.87–1.52 | 106 vs 92 | verified |
| Coronary revascularisation Coronary revascularization | 0.91 | 0.80–1.04 | 405 vs 441 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina pectoris | 0.98 | 0.76–1.26 | 122 vs 124 | verified |
Verbatim quotes (11)
- 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 1
The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% CI, 0.78 to 0.97
- Cardiovascular death · Results, Cardiovascular Outcomes; Table 1
Death from cardiovascular causes occurred in fewer patients in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93
- All-cause death · Results, Cardiovascular Outcomes; Table 1
The rate of death from any cause was also lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97
- Myocardial infarction · Table 1
Myocardial infarction § 292 (6.3) 1.6 339 (7.3) 1.9 0.86 (0.73–1.00) 0.046
- Stroke · Table 1
Stroke § 173 (3.7) 1.0 199 (4.3) 1.1 0.86 (0.71–1.06) 0.16
- Hospitalisation for heart failure · Table 1
Hospitalization for heart failure 218 (4.7) 1.2 248 (5.3) 1.4 0.87 (0.73–1.05) 0.14
- Kidney composite · Table 1; Results, Microvascular Outcomes
Nephropathy 268 (5.7) 1.5 337 (7.2) 1.9 0.78 (0.67–0.92) 0.003
- Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 1
Expanded composite outcome ‡ 948 (20.3) 5.3 1062 (22.7) 6.0 0.88 (0.81–0.96)
- Retinopathy complications · Table 1, microvascular outcomes
Retinopathy 106 (2.3) 0.6 92 (2.0) 0.5 1.15 (0.87–1.52)
- Coronary revascularisation · Table 1
Coronary revascularization 405 (8.7) 2.3 441 (9.4) 2.5 0.91 (0.80–1.04)
- Hospitalisation for unstable angina · Table 1
Hospitalization for unstable angina pectoris 122 (2.6) 0.7 124 (2.7) 0.7 0.98 (0.76–1.26)
Other indications
ELAD Liraglutide · Mild cognitive impairment + T2D · 48 weeks · n = 396 congress
MCI reversal 49.5 % vs 20.4 % on linagliptin (EASD 2026)
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline week 52 | — | — | −0.2 (−0.4 to +0.1) FDG-PET SUV | verified |
Verbatim quotes (1)
- Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline
The primary outcome showed no significant differences in cerebral glucose metabolism (difference = -0.17; 95% confidence interval: -0.39 to 0.06; P = 0.14) between the two groups.
Registered trials (52)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| INFLAM MOTION A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | Knee OA | Phase 2 | completed | 2025-06 → 2026-08 | 130 | Completed; results not in the atlas yet | NCT07225829 |
| MODY Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) | Other | Phase 2 | recruiting | 2025-05 → 2026-08 | 50 | recruiting | NCT07029009 |
| NCT06361238 Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery | Neurology | Phase 3 | recruiting | 2024-11 → 2027-03 | 260 | recruiting | NCT06361238 |
| NCT05965908 Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome | Obesity | Phase 3 | completed | 2024-08 → 2025-11 | 183 | Completed; results not in the atlas yet | NCT05965908 |
| NCT06559722 · China A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | T2D | Phase 3 | unknown | 2024-08 → 2025-10 | 510 | unknown | NCT06559722 |
| NCT05952882 Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility | Obesity | Phase 3 | unknown | 2023-11 → 2025-12 | 188 | unknown | NCT05952882 |
| NCT05767255 Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue | T2D | Phase 3 | unknown | 2022-12 → 2023-08 | 66 | unknown | NCT05767255 |
| NCT04763564 Efficacy of Liraglutide Therapy in Patients With IPAA | Other | Phase 2 | terminated | 2022-03 → 2023-10 | 8 | Terminated | NCT04763564 |
| NCT04199728 Use of a GLP-1R Agonist to Treat Opioid Use Disorder | Addiction | Phase 2 | completed | 2021-10 → 2023-09 | 27 | Completed; results not in the atlas yet | NCT04199728 |
| SCALE KIDS SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | Obesity | Phase 3 | active not recruiting | 2021-03 → 2023-08 | 78 | active not recruiting | NCT04775082 |
| NCT05360147 Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus | Alzheimer's | Phase 3 | completed | 2021-01 → 2021-04 | 30 | Completed; results not in the atlas yet | NCT05360147 |
| NCT04605861 The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients | Obesity | Phase 3 | completed | 2020-08 → 2022-12 | 414 | Completed; results not in the atlas yet | NCT04605861 |
| NCT04487743 Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities | Obesity | Phase 3 | unknown | 2020-05 → 2022-06 | 300 | unknown | NCT04487743 |
| NCT04525300 Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities | Obesity | Phase 3 | unknown | 2020-05 → 2022-06 | 300 | unknown | NCT04525300 |
| STEP 8 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Obesity | Phase 3 | completed | 2019-09 → 2021-03 | 338 | Completed; results not in the atlas yet | NCT04074161 |
| NCT03421119 Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes | T2D | Phase 3 | unknown | 2019-06 → 2019-12 | 300 | unknown | NCT03421119 |
| REMITiDegLira Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira | T2D | Phase 3 | completed | 2019-04 → 2022-06 | 159 | Completed; results not in the atlas yet | NCT03862716 |
| NATRIURETIC Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial | HFpEF | Phase 2 | completed | 2019-03 → 2021-03 | 6 | Completed; results not in the atlas yet | NCT04535960 |
| NCT03737240 IDegLira HIGH Trial | T2D | Phase 3 | completed | 2019-01 → 2022-07 | 145 | Completed; results not in the atlas yet | NCT03737240 |
| DAL Daily Liraglutide for Nicotine Dependence | Addiction | Phase 2 | completed | 2018-11 → 2022-05 | 40 | Completed; results not in the atlas yet | NCT03712098 |
| NCT03707171 Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus | Alzheimer's | Phase 3 | completed | 2018-10 → 2019-02 | 30 | Completed; results not in the atlas yet | NCT03707171 |
| SAXAPCOS Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Obesity | Phase 3 | completed | 2018-09 → 2021-02 | 88 | Completed; results not in the atlas yet | NCT03480022 |
| NCT03671733 Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | Obesity | Phase 3 | unknown | 2018-09 → 2022-09 | 150 | unknown | NCT03671733 |
| NCT03672812 The Use of Liraglutide in Brain Death | Other | Phase 3 | completed | 2018-09 → 2019-12 | 50 | Completed; results not in the atlas yet | NCT03672812 |
| NCT03374956 Individualized Obesity Pharmacotherapy | Obesity | Phase 3 | completed | 2017-12 → 2022-05 | 193 | Completed; results not in the atlas yet | NCT03374956 |
| BELIEVE Binge Eating Liraglutide Intervention | Addiction | Phase 3 | terminated | 2017-09 → 2019-09 | 36 | Terminated | NCT03279731 |
| NCT03115424 Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | Obesity | Phase 3 | completed | 2017-06 → 2023-10 | 46 | Completed; results not in the atlas yet | NCT03115424 |
| SUSTAIN 10 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2017-06 → 2018-07 | 577 | Completed; results not in the atlas yet | NCT03191396 |
| DUAL I China A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) | T2D | Phase 3 | completed | 2017-05 → 2019-06 | 720 | Completed; results not in the atlas yet | NCT03172494 |
| DUAL II China A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | T2D | Phase 3 | completed | 2017-05 → 2019-03 | 453 | Completed; results not in the atlas yet | NCT03175120 |
| NCT02953665 Safety and Efficacy of Liraglutide in Parkinson's Disease | Neurology | Phase 2 | completed | 2017-04 → 2022-08 | 63 | Completed; results not in the atlas yet | NCT02953665 |
| LIRA-ADD2SGLT2i LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. | T2D | Phase 3 | completed | 2017-03 → 2018-05 | 303 | Completed; results not in the atlas yet | NCT02964247 |
| SCALE Insulin Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin | Obesity | Phase 3 | completed | 2017-02 → 2018-09 | 396 | Completed; results not in the atlas yet | NCT02963922 |
| SCALE IBT Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | Obesity | Phase 3 | completed | 2017-02 → 2018-05 | 282 | Completed; results not in the atlas yet | NCT02963935 |
| PIONEER 9 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | T2D | Phase 3 | completed | 2017-01 → 2018-01 | 243 | Completed; results not in the atlas yet | NCT03018028 |
| LIRALUNG Study Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2016-10 → 2019-11 | 76 | Completed; results not in the atlas yet | NCT02889510 |
| DUAL II Japan A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs | T2D | Phase 3 | completed | 2016-09 → 2017-11 | 210 | Completed; results not in the atlas yet | NCT02911948 |
| NCT02918279 Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Obesity | Phase 3 | completed | 2016-09 → 2019-02 | 251 | Completed; results not in the atlas yet | NCT02918279 |
| PIONEER 4 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2016-08 → 2017-08 | 711 | Completed; results not in the atlas yet | NCT02863419 |
| NCT04325581 Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients | Obesity | Phase 3 | completed | 2016-08 → 2018-12 | 16 | Completed; results not in the atlas yet | NCT04325581 |
| LixiLan-G Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | T2D | Phase 3 | completed | 2016-07 → 2018-05 | 514 | Completed; results not in the atlas yet | NCT02787551 |
| i-LAB Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans | T2D | Phase 3 | unknown | 2016-06 → 2017-03 | 20 | unknown | NCT02718950 |
| DUAL IX A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2016-05 → 2017-09 | 420 | Completed; results not in the atlas yet | NCT02773368 |
| NCT03426085 The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes | Neurology | Phase 2 | unknown | 2016-05 → 2020-04 | 44 | unknown | NCT03426085 |
| DUAL VIII A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2016-01 → 2018-10 | 1012 | Completed; results not in the atlas yet | NCT02501161 |
| NCT02638805 Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | T2D | Phase 3 | completed | 2015-12 → 2017-10 | 136 | Completed; results not in the atlas yet | NCT02638805 |
| NCT02527200 Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Obesity | Phase 3 | completed | 2015-11 → 2020-11 | 56 | Completed; results not in the atlas yet | NCT02527200 |
| DUAL I Japan A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. | T2D | Phase 3 | completed | 2015-11 → 2017-12 | 819 | Completed; results not in the atlas yet | NCT02607306 |
| NCT02420262 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2015-07 → 2016-10 | 506 | Completed; results not in the atlas yet | NCT02420262 |
| NCT02505334 · Japan A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. | T2D | Phase 3 | completed | 2015-07 → 2017-05 | 635 | Completed; results not in the atlas yet | NCT02505334 |
| COGDYS-GLP1 Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists | Alzheimer's | Phase 3 | completed | 2015-05 → 2016-04 | 21 | Completed; results not in the atlas yet | NCT02423824 |
| LEADER Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | CV outcomes | Phase 3 | completed | 2010-08 → 2015-12 | 9341 | MACE HR 0.87 (0.78–0.97) | NCT01179048 |
Primary sources
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. PMID: 27295427.
- Zhou Zhang et al. Liraglutide and empagliflozin vs linagliptin on reversion of mild cognitive impairment in type 2 diabetes (LIGHT-MCI): a multicentre, randomised clinical trial. Abstract 140. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 24 Protecting the brain]
- Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nat Med. 2026;32(1):353-361. PMID: 41326666.
How to cite this page
Cite the primary publication for any single result; every value above links to it.